Cargando…
Driving Immune Responses in the Ovarian Tumor Microenvironment
Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence due to late stage diagnoses and acquired chem...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843421/ https://www.ncbi.nlm.nih.gov/pubmed/33520713 http://dx.doi.org/10.3389/fonc.2020.604084 |
_version_ | 1783644138076372992 |
---|---|
author | Ning, Franklin Cole, Christopher B. Annunziata, Christina M. |
author_facet | Ning, Franklin Cole, Christopher B. Annunziata, Christina M. |
author_sort | Ning, Franklin |
collection | PubMed |
description | Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence due to late stage diagnoses and acquired chemo-resistance. Recent approvals for bevacizumab and poly (ADP-ribose) polymerase inhibitors have improved treatment options but effective treatments are still limited in the recurrent setting. Immunotherapy has seen significant success in hematological and solid malignancies. However, effectiveness has been limited in ovarian cancer. This may be due to a highly immunosuppressive tumor microenvironment and a lack of tumor-specific antigens. Certain immune cell subsets, such as regulatory T cells and tumor-associated macrophages, have been implicated in ovarian cancer. Consequently, therapies augmenting the immune response, such as immune checkpoint inhibitors and dendritic cell vaccines, may be unable to properly enact their effector functions. A better understanding of the various interactions among immune cell subsets in the peritoneal microenvironment is necessary to develop efficacious therapies. This review will discuss various cell subsets in the ovarian tumor microenvironment, current immunotherapy modalities to target or augment these immune subsets, and treatment challenges. |
format | Online Article Text |
id | pubmed-7843421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78434212021-01-30 Driving Immune Responses in the Ovarian Tumor Microenvironment Ning, Franklin Cole, Christopher B. Annunziata, Christina M. Front Oncol Oncology Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence due to late stage diagnoses and acquired chemo-resistance. Recent approvals for bevacizumab and poly (ADP-ribose) polymerase inhibitors have improved treatment options but effective treatments are still limited in the recurrent setting. Immunotherapy has seen significant success in hematological and solid malignancies. However, effectiveness has been limited in ovarian cancer. This may be due to a highly immunosuppressive tumor microenvironment and a lack of tumor-specific antigens. Certain immune cell subsets, such as regulatory T cells and tumor-associated macrophages, have been implicated in ovarian cancer. Consequently, therapies augmenting the immune response, such as immune checkpoint inhibitors and dendritic cell vaccines, may be unable to properly enact their effector functions. A better understanding of the various interactions among immune cell subsets in the peritoneal microenvironment is necessary to develop efficacious therapies. This review will discuss various cell subsets in the ovarian tumor microenvironment, current immunotherapy modalities to target or augment these immune subsets, and treatment challenges. Frontiers Media S.A. 2021-01-15 /pmc/articles/PMC7843421/ /pubmed/33520713 http://dx.doi.org/10.3389/fonc.2020.604084 Text en Copyright © 2021 Ning, Cole and Annunziata http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ning, Franklin Cole, Christopher B. Annunziata, Christina M. Driving Immune Responses in the Ovarian Tumor Microenvironment |
title | Driving Immune Responses in the Ovarian Tumor Microenvironment |
title_full | Driving Immune Responses in the Ovarian Tumor Microenvironment |
title_fullStr | Driving Immune Responses in the Ovarian Tumor Microenvironment |
title_full_unstemmed | Driving Immune Responses in the Ovarian Tumor Microenvironment |
title_short | Driving Immune Responses in the Ovarian Tumor Microenvironment |
title_sort | driving immune responses in the ovarian tumor microenvironment |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843421/ https://www.ncbi.nlm.nih.gov/pubmed/33520713 http://dx.doi.org/10.3389/fonc.2020.604084 |
work_keys_str_mv | AT ningfranklin drivingimmuneresponsesintheovariantumormicroenvironment AT colechristopherb drivingimmuneresponsesintheovariantumormicroenvironment AT annunziatachristinam drivingimmuneresponsesintheovariantumormicroenvironment |